Not Yet Recruiting
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
NCT07531979
- Conditions
- Becotatug Vedotin, Chemotherapy, EGFR ADC, +3 more
- Locations
-
- Tianjin Medical University Cancer Institute and Hospital Tianjin, China